ABSTRACT. The balance between type 1 and type 2 T helper cells (the Th1-Th2 balance) is closely correlated with cancer, but the correlation in ovarian cancer remains unconfirmed. We investigated the Th1-Th2 balance for the diagnosis, treatment, and prognostic evaluation of ovarian cancer. Fifty healthy subjects and 50 ovarian cancer patients were recruited. The levels of various cytokines were determined in sera and ovarian cancer tissues using a Th1-Th2 human cytokine array. The usefulness of TNFa, IFNg, TNFa/IL-4, and IFNg/IL-4 for ovarian cancer diagnosis was assessed based on receiver operating characteristic (ROC) curves. The relationship between the TNFa/IL-4 level and survival time was investigated based on a survival curve. In the ovarian cancer patients, the levels of Th1 factors (IL-2, IFNg, TNFa, and IL-13) increased significantly in the sera, and IFNg and TNFa increased significantly in the ovarian cancer tissues. The levels of Th2 factors (IL-5 and IL-6) increased in the sera, but the level of IL-6 decreased significantly in the ovarian cancer tissues. Serum TNFa/IL-4 and IFNg/IL-4 levels increased significantly in the peripheral blood of the ovarian cancer patients. ROC curve analysis revealed that TNFa, IFNg, TNFa/IL-4, and IFNg/IL-4 levels are useful for ovarian cancer diagnosis, with area under the curve values of 0.831, 0.753, 0.846, and 0.803, respectively. The TNFa/IL-4 level in the ovarian cancer patients was positively correlated with survival time, and the Th1-Th2 balance shifted toward Th1 in the ovarian cancer patients. The TNFa/IL-4 ratio might be useful for the diagnosis and prognosis of ovarian cancer.
INTRODUCTION
A shift in the balance between type 1 and type 2 T helper cells (Th1 and Th2 cells) is considered an important factor in cancer development (Shurin et al., 1999; Chen et al., 2004; Green et al., 2010) . Th1 cells mainly secrete IL-2, TNFa, IFNg, and other cytokines to promote cell immunity (Mills et al., 1993) , thereby playing an important role in anti-viral (Zhang et al., 2014) and anti-tumor activity. Th2 cells mainly secrete IL-4, IL-5, IL-6, IL-10, and other cytokines to induce humoral immunity, thereby playing an important role in foreign antigen clearance (Kidd, 2003) . Th1 and Th2 check and balance each other in the body. Many studies have indicated that Th1-Th2 imbalance allows tumor cells to escape immune surveillance and clearance; thus, a shift in the Th1-Th2 balance is an important factor in the development and progression of tumors (Clerici et al., 1996; Jones et al., 2002) . Th1-Th2 imbalance has been observed in a variety of cancers, and has been used to assess tumor progression and prognosis in clinical practice (Wada et al., 2003; Zhao et al., 2008; Block et al., 2011) .
Ovarian cancer represents approximately 3% of cancers in women but causes more deaths than any other cancer of the female reproductive system (Chornokur et al., 2013) . The role of the Th1-Th2 balance in ovarian cancer has been described. Aoki et al. (2000) used flow cytometry to investigate changes in the Th1-Th2 balance after chemotherapy and granulocytecolony stimulating factor (G-CSF) injection in ovarian cancer patients, and determined that the balance shifted toward Th2 10 days after chemotherapy, and toward Th1 after G-CSF treatment. However, these authors did not determine the Th1-Th2 balance before treatment. The immune system is greatly affected by cancer treatment; therefore, their findings do not reflect the Th1-Th2 status before treatment. Kusuda et al. (2005) determined the mRNA levels of TNFa, IFNg, and IL-12p40 in Th1 cells, and those of IL-6 and IL-10 in Th2 cells in ovarian cancer tissues by quantitative polymerase chain reaction. They thereby determined the correlations between those mRNA levels and the clinical stage, histological grade, and histological type of ovarian cancer. The authors concluded that the expression levels of IFNg, IL-12p40, and IL-6 might represent useful prognostic molecular markers for patients with advanced ovarian cancer, but did not investigate whether the absolute level of these markers or the Th1-Th2 balance in peripheral blood was relevant to the disease. Zhu et al. (2010) investigated the levels of IFNg, TNFa, IL-10, IL-5, IL-4, and IL-2 before surgery for ovarian cancer using cytokine arrays, and found that IL-2 and IL-10 levels are paired predictors of survival. However, these authors did not investigate alterations in Th1-Th2 levels in cancer tissue.
In this study, the levels of relevant cytokines were quantitatively detected in the sera and cancer tissues from ovarian cancer patients using Th1-Th2 human cytokine arrays, and the usefulness of these measurements for the diagnosis and prognosis of ovarian cancer was investigated.
MATERIAL AND METHODS

Patients
Fifty ovarian cancer patients who received treatment at the Panyu Maternal and Child Care Service Centre and at the First Affiliated Hospital of Guangzhou Medical University between 2012 and 2014 were recruited. The New International Ovarian Cancer Diagnostic Criteria were used to diagnose and grade ovarian cancer (Sugiyama and Kou, 2008; Höhn et al., 2014) . Patients were diagnosed for the first time with ovarian cancer and they had not received any drug or surgery treatment before the serum samples were collected. Ovarian cancer tissues and corresponding adjacent tissues or tissue from the opposite ovary were separated under a microscope after surgery and immediately frozen at -80°C.
Fifty healthy subjects undergoing health examinations in the same hospital were selected as controls. The healthy subjects were age-matched with the patients and had no history of gynecological disease.
This study was approved by the Ethics Committee of Guangzhou Medical University. Informed consent was obtained from all patients on the day of admission.
Protein extraction from cancer tissue
Total protein was extracted from tumor tissue using radio-immunoprecipitation assay (RIPA) buffer (Solarbio Biotech Corp., Beijing, China) following the manufacturer instructions. Briefly, ovarian cancer tissues were lysed for use in antibody array analysis in RIPA buffer containing 1% phenylmethylsulfonyl fluoride (Solarbio Biotech Corp.), and homogenized using a microtissue grinder (Kimble Chase, Thailand). The supernatants were collected after centrifugation at 14,000 g and 4°C for 15 min. The protein concentration was determined using a bicinchoninic acid assay (Solarbio Biotech Corp.).
Serum cytokine profile obtained using a human cytokine microarray
A commercial quantitative microarray (Th1-Th2 Human Cytokine Array 1, BD, USA) was used to obtain the cytokine expression profile of the serum samples according to the manufacturer instructions, and the results were analyzed using the RayBiotech Q-Analyzer program. Briefly, after a 30-min incubation with blocking buffer, the glass chips were washed, and each well was overlaid with 100 mL diluted sample. After overnight incubation at 4°C and extensive washing, a biotin-labeled detection antibody was added and left for 1 h. The chips were then rinsed and incubated with Alexa Fluor 555-conjugated streptavidin for 1 h at room temperature. The fluorescence was then recorded (555 nm excitation and 655 nm emission) using a GenePix 4000B laser scanner (Axon Instruments, Foster City, CA, USA).
Statistical analysis
All results and relative Th1-Th2 ratios are reported as means ± SE. Statistical analysis was performed using the SPSS 13.0 software. The paired Student t-test was used to compare groups. Significance was tested using the homogeneity test (P < 0.05 was considered significant).
RESULTS
Expression of Th1-Th2 in healthy subjects and in the serum, cancer tissue, and adjacent tissue of ovarian cancer patients A Th1-Th2 human cytokine array was used to quantitatively detect the expression of Th1 factors (IL-2, IL-13, IFNg, and TNFa) and Th2 factors (IL-4, IL-5, IL-6, and IL-10) in the peripheral blood of healthy individuals and patients with ovarian cancer before treatment, as well as in ovarian cancer tissues and adjacent tissues. The results are shown in Figure 1 and Table 1 . Compared with the healthy controls, serum Th1 cytokine levels were generally increased in the ovarian cancer patients as follows: IL-2 was increased 1.42-fold (paired t-test; P = 0.023; N = 50 for each group); IL-13 was increased 1.73-fold (paired t-test; P = 0.012; N = 50 for each group); IFNg was increased 1.52-fold (paired t-test; P = 0.045; N = 50 for each group); and TNFa was increased 1.91-fold (paired t-test; P = 0.013; N = 50 for each group). Th2 cytokines were generally increased in patients with ovarian cancer as follows: IL-6 was increased 2.56-fold (paired t-test; P = 0.014; N = 50 for each group), and IL-5 was increased 2.41-fold (paired t-test; P = 0.023; N = 50 for each group). However, no significant change was observed in IL-4, the most important Th2 cytokine. Analysis of ovarian cancer tissue and adjacent tissue lysates revealed that the expression of Th1 cytokines (namely IFNg and TNFa) was significantly increased in the cancer tissues: IFNg was increased 4.67-fold (paired t-test; P = 0.011; N = 50 for each group), and TNFa was increased 1.63-fold (paired t-test; P = 0.031; N = 50 for each group). IL-6, a Th2 cytokine, was significantly decreased in cancer tissues (0.07-fold; paired t-test; P = 0.01; N = 50 for each group). Thus, the immune system of the ovarian cancer patients was shifted toward Th1 cytokines compared with the healthy individuals.
Differences in the ratios of various cytokines in ovarian cancer patients
To investigate the diagnostic value of changes in the Th1-Th2 balance for ovarian cancer, serum TNFa/IL-4 and IFNg/IL-4 ratios (Tang et al., 2015) were used as indicators of the Th1-Th2 balance (Figure 2A and B) . The TNFa/IL-4 and IFNg/IL-4 ratios were significantly higher in the sera of patients with ovarian cancer (P = 0.0134). Receiver operating characteristic (ROC) curve analysis revealed that the TNFa/IL-4 ratio differed more than the IFNg/IL-4 ratio or the levels of IL-4, TNFa, or IFNg between the healthy controls and the ovarian cancer patients. The area under the curve (AUC) values for the TNFa/IL-4 ratio, the IFNg/IL-4 ratio, IL-4, TNFa, and IFNg were 0.846, 0.803, 0.314, 0.831, and 0.753, respectively ( Figure 2C ).
Usefulness of the serum TNFα/IL-4 ratio for the prognostic evaluation of ovarian cancer treatment
The 50 patients with ovarian cancer were classified into three groups according to the TNFa/IL-4 ratio (group 1, more than 5; group 2, 2-5; and group 3, less than 2), and changes in the level of cancer antigen 125 (CA125) were determined in each group after treatment. CA125 levels decreased significantly in all groups after ovarian cancer treatment, then gradually increased. In the 4th and 5th month after treatment, CA125 levels were significantly higher in groups 2 and 3 than in group 1, thus indicating their poor prognoses. Life-cycle curve analysis revealed that survival time was significantly longer in group 1 than in groups 2 and 3. Rank test analysis demonstrated that the TNFa/IL-4 ratio was significantly correlated with survival time (P = 0.021; Figure 3 ).
Data are reported as median ± SE. TNFa/IL-4 ratio (group 1, more than 5; group 2, 2-5; and group 3, less than 2), and changes in the level of cancer antigen 125 (CA125) were determined in each group after treatment. CA125 levels decreased significantly in all groups after ovarian cancer treatment, then gradually increased. In the 4th and 5th month after treatment, CA125 levels were significantly higher in groups 2 and 3 than in group 1, thus indicating their poor prognoses. Life-cycle curve analysis revealed that survival time was significantly longer in group 1 than in groups 2 and 3. Rank test analysis demonstrated that the TNFa/IL-4 ratio was significantly correlated with survival time (P = 0.021; Figure 3 ). Cancer antigen 125 (CA125) levels changed after ovarian cancer treatment. All CA125 levels had decreased significantly 1 month after treatment, and then they gradually increased. In the 4th and 5th month after treatment, the CA125 levels in groups 2 and 3 were significantly higher than that in group 1. B. Life-cycle curve analysis revealed that the survival time in group 1 was significantly longer than that in groups 2 and 3.
DISCUSSION
The Th1-Th2 balance has been reported to play an important role in the development and progression of many cancers, but its role in ovarian cancer remains unclear. In this study, Th1-Th2 levels were quantified in the sera and cancer tissues of patients with ovarian cancer before treatment using antibody arrays. Th1 cytokines (IL-2, TNFa, IFNg, and IL-13) were significantly increased in the sera and cancer tissues of the ovarian cancer patients. Of the Th2 cytokines, only IL-6 and IL-5 were increased in cancer tissues, and IL-6 was significantly decreased. Compared with the healthy controls, IFNg/IL-4 and TNFa/IL-4 ratios were significantly increased in the peripheral blood of the ovarian cancer patients, indicating that the Th1-Th2 balance was shifted toward Th1, representing an anti-tumor shift. These results also indirectly demonstrate that an altered Th1-Th2 balance might be caused by ovarian cancer rather than the reverse relationship. According to traditional theory, shifting the Th1-Th2 balance toward Th2 enables tumor cells to avoid immune surveillance, leading to tumorigenesis (Clerici et al., 1996) . However, we observed that the Th1-Th2 balance was shifted toward antitumor Th1 before treatment in the ovarian cancer patients. We also observed that IL-6 was highly expressed in cancer-adjacent tissues but was significantly decreased in ovarian cancer tissues compared with adjacent tissues, consistent with the mRNA data (Kusuda et al., 2005) . Therefore, IL-6 might be secreted by cancer-adjacent tissues and released into the blood.
This study also indicated that TNFa, IFNg, and the TNFa/IL-4 and IFNg/IL-4 ratios are useful for the diagnosis of ovarian cancer. The TNFa/IL-4 ratio provided better discriminating power than the use of TNFa or IFNg alone. ROC curve analysis demonstrated that the TNFa/ IL-4 ratio differed more significantly than the IFNg/IL-4 ratio or the levels of IL-4, TNFa, or IFNg between the healthy controls and the ovarian cancer patients. The AUC values were 0.846, 0.803, 0.314, 0.831, and 0.753 for the TNFa/IL-4 ratio, the IFNg/IL-4 ratio, IL-4, TNFa, and IFNg, respectively. However, because TNFa, IFNg, IL-4, and other factors are influenced by a variety of diseases, their specificity in the detection of ovarian cancer should be verified.
Additionally, we determined that the TNFa/IL-4 ratio was positively correlated with the prognosis of ovarian cancer; higher TNFa/IL-4 ratios indicated longer patient survival. This result is consistent with previous findings that a high Th1-Th2 ratio in tumors predicts good prognosis in gastric and liver cancers (Nagai et al., 2008; Chang et al., 2014) . However, owing to the inconsistencies regarding clinical stage and patient age, further experiments are required to confirm the relevance of ovarian cancer staging and age to the Th1-Th2 balance.
This study had several limitations. The sample size was small. Therefore, studies with a larger sample size are needed to confirm the results of this study. Although the rank test demonstrated that the TNFa/IL-4 ratio was positively correlated with prognosis, additional clinical samples are needed for verification. Second, the clinical stage was inconsistent. All 50 ovarian cancer cases studied here ranged from stage 1 to stage 3. Third, the patients differed in age. Although the patients and healthy controls were age-matched, their ages ranged from 40 to 65 years. The influence of the factors mentioned above on Th1-Th2 balance requires further validation. In future studies, we will increase the sample size and refine the clinical information to further clarify the effect of the Th1-Th2 balance on ovarian cancer.
This study is the first to reveal a correlation between Th1-Th2 balance and the diagnosis and prognosis of ovarian cancer; in particular, the TNFa/IL-4 ratio was identified as relevant for the diagnosis and prognostic evaluation of ovarian cancer. Thus, the Th1-Th2 balance represents a valuable tool for use in clinical practice.
